By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico - 2Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- 3As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- 4Finding Ideal Date Spots for Two or three Encounters
- 5Study reveals links between global food systems, obesity, and climate change
- 4 Dazzling And Well known Island Objections In US
- Report: Russian military pressuring students to work as drone pilots
- 5 Critical Rules For Business Regulation Chiefs
- Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- Chicago reports first rabies-positive dog in 61 years. What we know.
- My Excursion to a Better Way of life: Health Experiences
- The Best 10 Innovation Advancements of the Year
- Exploring ways to reduce the impact of space junk on Earth
